Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tarsus Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Tarsus Pharmaceuticals Inc’s stock price such as:

• Tarsus Pharmaceuticals Inc’s current stock price and volume
• Why Tarsus Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for TARS from analysts
• TARS’s stock price momentum as measured by its relative strength

About Tarsus Pharmaceuticals Inc (TARS)

Before we jump into Tarsus Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.

Want to learn more about Tarsus Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc’s Stock Price as of Market Close

As of June 17, 2024, 4:00 PM, CST, Tarsus Pharmaceuticals Inc’s stock price was $28.84.

Tarsus Pharmaceuticals Inc is down 6.91% from its previous closing price of $30.98.

During the last market session, Tarsus Pharmaceuticals Inc’s stock traded between $29.79 and $32.97. Currently, there are 35.30 million shares of Tarsus Pharmaceuticals Inc stock available for purchase.

Unfortunately, Tarsus Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Tarsus Pharmaceuticals Inc Stock Price History

Tarsus Pharmaceuticals Inc’s (TARS) price is currently down 12.5% so far this month.

During the month of June, Tarsus Pharmaceuticals Inc’s stock price has reached a high of $34.77 and a low of $28.66.

Over the last year, Tarsus Pharmaceuticals Inc has hit prices as high as $42.50 and as low as $12.57. Year to date, Tarsus Pharmaceuticals Inc’s stock is up 96.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tarsus Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 14, 2024, there were 0 analysts who downgraded Tarsus Pharmaceuticals Inc’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Tarsus Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tarsus Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Tarsus Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tarsus Pharmaceuticals Inc (TARS) by visiting AAII Stock Evaluator.

Relative Price Strength of Tarsus Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 14, 2024, Tarsus Pharmaceuticals Inc has a weighted four-quarter relative price strength of 7.37%, which translates to a Momentum Score of 86 and is considered to be Very Strong.

Want to learn more about how Tarsus Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tarsus Pharmaceuticals Inc Stock Price: Bottom Line

As of June 17, 2024, Tarsus Pharmaceuticals Inc’s stock price is $28.84, which is down 6.91% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tarsus Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.